Research company Peptonic Medical reduced revenue and its loss in the second quarter. Going forward, the focus is on stronger products and higher sales. Revenue fell 51.0 percent to SEK 2.4 million (4.9).Operating result was SEK -3.7 million (-7.5). Net result after tax was SEK -3.8 million (-3.5)."In the first quarter, I described how we had created the conditions for Peptonic's next phase. During the second quarter, we began turning these conditions into concrete commercial development. Our international launch, the ongoing broadening of the product portfolio and a strengthened financial position give us a good foundation for the continued work," interim CEO Daniel Rudeklint states in the reportHe continues. "Our focus going forward is clear: stronger products, higher sales and continued brand building. We will continue to develop our products, build on ourpartnerships and create the conditions for long-term and sustainable growth."Peptonic Medical has previously carried out a reconstruction. Peptonic Medical, SEK millionQ2-2026Q2-2025ChangeNet sales2.44.9-51.0%Operating result-3.7-7.5Net result-3.8-3.5